ARCHIVES

Collaborative Drug Development Groups Clear BSC Overview, Natural Products RFA To Proceed

This article is from The Cancer Letter archive.

Vol. 14 No. 24 | June 10, 1988

Download PDF Visit The Full Archive

Related Articles

FDA, NCI Seek Compromise On Survival Endpoints

June 16, 1989

DCT Board Ok’s PA, BRM Contract Concepts

October 30, 1992

In Brief: Magnuson Subcommittee Increases NCI, NIH Budgets Despite Trimming Labor-HEW Bill By $250 Million

August 23, 1974

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

October 14, 2005

In Brief: Robert Bast Succeeds Singleton As Director Of Duke Cancer Center; Robert Bell Deputy

August 14, 1987

New Phase III Trial Reviews Approve 25%; Should Trialists Worry? Not Yet,

January 19, 2007